Too much or not enough heparin and histamine intolerance

By

A connection between heparin and histamine intolerance (HIT) does indeed exist, because heparin influences the activity of diamine oxidase (DAO), the enzyme that breaks down histamine in the intestines and blood.

In short: Both too much and too little heparin can cause problems in histamine intolerance, because heparin is a natural regulator of histamine breakdown.

1. Too much heparin (e.g., from heparin injections)

If you receive high-dose heparin (e.g., injections to prevent thrombosis after surgery), this can temporarily worsen histamine intolerance dramatically.

• DAO blockade: Heparin releases the enzyme DAO from tissues. In the short term, this leads to an apparent increase, but with chronic use or high doses, DAO is consumed, excreted, or blocked more rapidly.

• Consequence: The body can no longer properly break down histamine from food. Typical HIT symptoms occur, such as headaches, flushing, gastrointestinal problems, or a racing heart, even when following a low-histamine diet.

2. Too little heparin (the body’s own heparin)

Heparin is naturally produced in the body by mast cells, just like histamine. Both substances are often released together.

• Natural counterbalance: Endogenous (body-produced) heparin actually has a protective function. It helps activate DAO to neutralize excess histamine.

• Mast cell activation (MCAS): If your mast cells are dysregulated (as is often the case with severe histamine intolerance or mast cell activation syndrome), the balance between heparin and histamine may be disturbed. If the body lacks the regulatory effect of sufficient functioning heparin, histamine activity can become uncontrolled.

Summary: Side-by-side comparison

Condition

Effect on histamine levels

Main cause / mechanism

Too much heparin (medicinal)

Histamine rises because the breakdown enzyme DAO is blocked or depleted.

Thrombosis-prevention injections, infusions.

Too little heparin (endogenous)

Histamine has a stronger effect because the natural protective and regulatory mechanism is absent.

Mast cell dysfunction (MCAS).

How heparin is tested depends entirely on whether it is medicinal heparin (injections/infusions) or endogenous heparin (from mast cells in MCAS).

Because normal plasma generally contains no measurable heparin, different methods are used depending on the clinical question:

1. Testing for medicinal heparin (treatment monitoring)

If you are receiving heparin as a medication and its effect or dosage needs to be checked, this is done using standardized blood tests at a doctor’s office or hospital:

• Anti-Xa assay (heparin anti-Xa): This is the most precise and modern test. It directly measures the functional activity of heparin in blood plasma. It is used for both low-molecular-weight heparin (LMWH, e.g., Clexane) and unfractionated heparin (UFH).

• aPTT (activated partial thromboplastin time): A classic, widely used coagulation test. It measures how many seconds blood takes to clot. Because heparin delays clotting, the aPTT becomes prolonged. However, it is more sensitive to interfering factors.

• ACT (activated clotting time): Usually used at the bedside (point of care) during surgery or dialysis to rapidly monitor high-dose heparin administration.

2. Testing for endogenous heparin (when MCAS is suspected)

When activated, mast cells release natural endogenous heparin as well as histamine. However, detecting it in the context of a mast cell disorder is much more challenging in routine laboratory practice:

• Plasma heparin level (pHL): Specialized laboratories can determine baseline endogenous heparin status in blood plasma. In studies, this marker was often found to be more sensitive than conventional tryptase in patients with mast cell activation syndrome (MCAS).

• Thromboelastography (TEG) with heparinase: An advanced functional blood-clotting test. If the laboratory adds the enzyme heparinase to blood and previously delayed clotting suddenly normalizes, this proves that too much endogenous heparin was circulating in the blood.

• Important preanalytical handling (“chilled plasma”): Endogenous heparin is extremely unstable. As soon as blood is drawn, platelets activate and neutralize heparin. Therefore, for mast cell testing, the blood must immediately be chilled on ice, centrifuged, and deep-frozen (“stat chilled plasma heparin”).

VWD and Heparin

The combination of von Willebrand disease (VWD) and heparin is highly medically relevant because heparin directly blocks the function of von Willebrand factor (VWF).

For patients with VWD, this means a greatly increased risk of unpredictable and severe bleeding.

The biological mechanism: Why heparin blocks VWF

Von Willebrand factor acts like a biological “glue”: it allows platelets (thrombocytes) to adhere to injured blood vessel walls (via the so-called GPIb receptor).

• Direct binding: Heparin has a binding site that docks precisely onto the A1 domain of von Willebrand factor.

• Loss of function: Once heparin binds to VWF, it blocks its ability to attach to platelets. Medical studies show that heparin can reduce VWF activity (measured as ristocetin cofactor activity) in the blood by up to 58%.

• Double effect: Heparin therefore not only thins the blood through the conventional coagulation system (antithrombin), but also disables primary hemostasis mediated by platelets.

Clinical risks in VWD

1. Massively increased bleeding risk

Because patients with VWD already have too little VWF or defective VWF, additional blockade by heparin can almost completely disable hemostasis. For this reason, blood thinners such as heparin are considered strictly contraindicated in known von Willebrand disease unless there is a life-threatening emergency (e.g., a heart attack) in which the risk of thrombosis outweighs the bleeding risk.

2. Unpredictability during surgery

The situation is particularly critical during major operations (such as open-heart surgery with a heart-lung machine), where extremely high doses of heparin must routinely be used. With undiagnosed VWD or incorrect dosing, severe surgical bleeding that is difficult to control may occur and often cannot be reliably predicted by standard clotting tests (such as aPTT).

3. Heparin resistance (the other side of the coin)

In rare cases, the interaction can also work in reverse: If a patient has extremely high levels of VWF in the blood (e.g., due to inflammation), this VWF can bind and neutralize much of the administered heparin. The heparin then no longer works properly, which is known as heparin resistance.

Important practical considerations (e.g., during pregnancy or surgery)

If you have VWD and face a situation requiring heparin (e.g., thrombosis prevention after childbirth or during bed rest), strict guidelines apply:

• Low-molecular-weight heparin (LMWH): If thrombosis prevention is absolutely necessary, low-molecular-weight heparin (e.g., Clexane) is preferred. It inhibits von Willebrand factor much less strongly than conventional unfractionated heparin.

• Hematological supervision: Any heparin administration must be closely coordinated with a coagulation center (hematologist) to raise VWF and factor VIII levels beforehand with medication (e.g., desmopressin or VWF concentrates).

Factor II and Factor V Leiden are the two most common inherited genetic risk factors for blood clots (thrombosis).

Together, they lead to what is known as thrombophilia (an abnormally increased tendency of the blood to clot). Both mutations affect important components of the coagulation cascade.

1. Factor V Leiden mutation (APC resistance)

This is the most common inherited risk factor for thrombosis in Western populations (approximately 5% of people in Europe carry this mutation).

• The problem: The body has a natural “braking system” for coagulation: activated protein C (APC). Normally, APC breaks down activated factor V to stop clotting.

• The mutation: Due to a tiny genetic error (point mutation), factor V in the “Leiden” variant is altered so that protein C can no longer bind to it (APC resistance).

• Consequence: The brake fails. Factor V remains continuously active, and blood clots much too quickly.

2. Factor II mutation (prothrombin mutation G20210A)

This is the second most common genetic risk factor for thrombosis. Factor II is the protein prothrombin, the direct precursor of thrombin (the main building block of blood clots).

• The problem/mutation: A mutation in the prothrombin gene causes the body simply to produce too much prothrombin.

• Consequence: An excessive amount of this clotting factor circulates in the blood continuously. As soon as the coagulation cascade is triggered even slightly, the reaction overshoots and a clot forms much more quickly.

Direct comparison of risk

Thrombosis risk depends greatly on whether the mutation was inherited from only one parent (heterozygous) or both parents (homozygous).

Mutation

Type

Increase in thrombosis risk

Factor V Leiden

Heterozygous (1 altered gene)

approx. 3–8 times higher

Factor V Leiden

Homozygous (both genes altered)

approx. 50–100 times higher

Factor II (prothrombin)

Heterozygous (1 altered gene)

approx. 2–3 times higher

Factor II (prothrombin)

Homozygous (both genes altered)

Extremely rare, very high risk

The phenomenon of “combined heterozygosity”

It becomes particularly relevant when a patient carries both mutations in the heterozygous state (that is, Factor V Leiden and the Factor II mutation, each on one gene copy). In this case, the risks do not simply add up; they multiply. The thrombosis risk is then similar to that of a homozygous Factor V Leiden mutation.

How does this relate to your previous questions (VWD, heparin, histamine)?

A complex connection in hematology:

1. Opposing forces: Von Willebrand disease (VWD) theoretically provides some protection against thrombosis because it impairs hemostasis (bleeding tendency). Factor V Leiden and Factor II do the exact opposite: they increase thrombosis risk. If both are present, their effects can partially mask one another or lead to completely unpredictable situations during surgery.

2. Heparin therapy: If someone has been diagnosed with Factor V Leiden or a Factor II mutation, that person almost always needs heparin injections for prevention in high-risk situations (e.g., long-haul flights, a leg in a cast, pregnancy, surgery).

3. The histamine dilemma: If this patient also has histamine intolerance or MCAS, the heparin needed for prevention (as described in the first answer) may block DAO and trigger severe histamine flare-ups.

A combination of the Factor II (prothrombin) mutation and Factor V Leiden mutation (double heterozygosity) means a significantly increased risk of venous blood clots (thrombosis and pulmonary embolism), because the clot-promoting effects of the two genetic defects reinforce each other.

What the diagnosis does in the body

• Two simultaneous problems: You have both altered instructions for factor V (Leiden = resistance to the natural coagulation brake, protein C) and overproduction of prothrombin (factor II).

• Increased tendency to clot: Blood tends to form clumps more quickly because both the coagulation “brake” is impaired and too much starting material is present.

• Amplification by triggers: Thrombosis risk rises especially sharply when classic triggers are added, such as surgery, prolonged sitting (flights/car travel), pregnancy, or estrogen-containing medications (the pill).

What to watch for in everyday life

• Prevention in high-risk situations: In situations with increased thrombosis risk (e.g., after surgery, with more serious injuries, or during prolonged bed rest), medically prescribed thrombosis prevention (often with low-molecular-weight heparin) is essential.

• Connection to histamine: Since histamine intolerance is a concern in your case, treating physicians should be informed of this intolerance if preventive heparin administration becomes necessary.

• No permanent medication necessary: The diagnosis alone, without a previous event, generally does not require lifelong blood thinning in everyday life, but rather targeted protection in high-risk situations.

References:

The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing
https://pmc.ncbi.nlm.nih.gov/articles/PMC6566593/

Heparin, von Willebrand Factor Interaction to Predict Bleeding During Cardiopulmonary Bypass
https://www.hematologyadvisor.com/news/predicting-bleeding-in-cardiopulmonary-bypass-remains-challenging/

von Willebrand Disease
https://www.onkopedia.com/en/onkopedia/guidelines/von-willebrand-disease/@@guideline/html/index.html

The heparin-von Willebrand factor interaction and conventional tests of haemostasis – the challenges in predicting bleeding in cardiopulmonary bypass
https://onlinelibrary.wiley.com/doi/10.1111/bjh.17263

Thrombophilia: Factor V Leiden and Prothrombin Gene Mutation
https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=THROMBOPHILIAFACTORVLEIDENANDP

Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A
https://www.ahajournals.org/doi/10.1161/circulationaha.109.906347

Von Willebrand Disease
https://www.msdmanuals.com/de/profi/h%C3%A4matologie/thrombozytopenie-und-thrombozyt%C3%A4re-dysfunktionen/von-willebrand-syndromhttps://www.msdmanuals.com/de/profi/h%C3%A4matologie/thrombozytopenie-und-thrombozyt%C3%A4re-dysfunktionen/von-willebrand-syndrom

Histamine Intolerance: Symptoms, Dietary Triggers, Medications, Diagnosis, and Management
https://swaresearch.blogspot.com/2026/10/histamine-intolerance-how-to-recognize.html


© 2020-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9 

Comments

Post a Comment

Popular posts from this blog

Schnitzler Syndrome: A Rare Autoinflammatory Disorder

By
Schnitzler syndrome is a rare, chronic autoinflammatory disease characterized by chronic urticaria (hives), recurrent fever, joint pain, and monoclonal gammopathy (abnormal proteins in the blood). First described by Dr. Liliane Schnitzler in 1972 , this condition is often misdiagnosed, leading to years of untreated symptoms before a correct diagnosis is made. The case report, " A 58-Year-Old Woman With Urticaria, Fever, and Joint Pain " , describes a case that closely aligns with my own experience with this challenging disorder. Key Features of Schnitzler Syndrome Schnitzler syndrome presents with a characteristic set of symptoms, though not all patients experience them in the same way: Chronic Urticaria (Hives) – Persistent, non-itchy or mildly itchy red patches that do not respond to antihistamines. Monoclonal Gammopathy (IgM or IgG type) – Abnormal monoclonal immunoglobulin detected in the blood (most commonly IgM ). Recurrent Fever – Unexplained fever episodes, often...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Acute Flaccid Myelitis (AFM): Understanding the “Polio-like” Illness Affecting the Spinal Cord

By
Acute flaccid myelitis (AFM) is a rare but serious neurological disorder that primarily affects children and results in sudden weakness or paralysis in the limbs. Often referred to as a “polio-like” illness, AFM has drawn growing attention over the past decade due to its similarities with poliomyelitis and its seasonal spikes in reported cases. While AFM remains uncommon, its potential severity—and the uncertainty surrounding its causes—make it an important condition for clinicians, parents, and public health officials to understand. What Is Acute Flaccid Myelitis? AFM is a condition that affects the gray matter of the spinal cord , where it damages motor neurons responsible for muscle movement. This leads to acute, flaccid paralysis , meaning muscles become limp and weak, often without warning. The condition can progress rapidly, and in some cases, the weakness can become long-lasting or even permanent. Although its symptoms resemble those of poliovirus infection, AFM is not cau...
Read more

Very Long-Chain Fatty Acids (VLCFAs) X-ALD and Spinal Muscular Atrophy (SMA): Exploring the Connection

By
Image
Introduction: White Brain Matter, VLCFAs, and X-ALD X-linked Adrenoleukodystrophy (X-ALD) is a rare inherited metabolic disorder and a major cause of progressive neurodegeneration in children—sometimes referred to as “childhood dementia.” Across related conditions, prevalence can range from approximately 1 in 2,000 to 1 in 500,000 newborns. Among its forms, childhood cerebral X-ALD is the most severe, marked by rapid inflammatory demyelination in the brain and often fatal outcomes if not treated early. At the core of X-ALD is a disruption in the metabolism of Very Long-Chain Fatty Acids (VLCFAs). Normally, these fatty acids are broken down in peroxisomes—specialized structures within cells that help maintain metabolic balance. In X-ALD, a mutation in the ABCD1 gene impairs this function, causing VLCFAs to accumulate, particularly in the white matter of the brain, spinal cord, and adrenal glands. This accumulation leads to demyelination, adrenal insufficiency (Addison’s disease), an...
Read more

Polio and Post-Polio Syndrome (PPS): Summary and Key Insights

By
Image
Abstract Post-Polio Syndrome (PPS) develops in some survivors of paralytic poliomyelitis decades after recovery and is characterized by new or progressive muscle weakness, fatigue, pain, and reduced endurance. The prevailing pathophysiological model attributes PPS primarily to the gradual deterioration of enlarged motor units formed through compensatory axonal sprouting after the initial poliovirus (PV) infection. Although immune dysregulation and chronic systemic inflammation have been investigated as potential mechanisms, current evidence does not support classifying PPS as a primarily dysimmune or chronically inflammatory disorder. Nevertheless, the possible persistence of poliovirus-derived material and its biological significance remain subjects of investigation. Evidence for viral persistence has been reported in subsets of patients with PPS. In one study of 47 patients, elevated anti-poliovirus IgM antibodies were detected in some individuals, with titers reaching 1:250 compared...
Read more

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By
Image
Important update: My experiences have now been formally verified following several years of dismissal. Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations https://link.springer.com/article/10.1186/s12985-025-03032-x  ----------------------------------------- Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially pres...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By
Image
My Journey Toward Understanding Spinal Muscular Atrophy (SMA) Today, I better understand why Spinal Muscular Atrophy (SMA) received so little attention, particularly during the 1950s. This complex and debilitating genetic disorder was poorly understood, and patients’ symptoms could easily be minimized, misinterpreted, or dismissed. Even today, SMA can present significant diagnostic challenges, particularly in adults with complex medical histories. In my own experience, comprehensive investigations into the underlying cause of progressive muscle weakness were not always pursued. A Long and Complicated Diagnostic Journey In 2008, while being investigated for permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II .  I underwent surgery in 2009, but unfortunately, my symptoms did not improve. In 2010, a DNA test identified a genetic marker involving the ACTN3 gene . Further information about ACTN3 and its possible relation...
Read more

The Impact of Acids on Muscular and Vascular Systems: Potential Negative Outcomes

By
This is ongoing research, and updates will be included as soon as they become available. A kidney transplant recipient with acute SARS-CoV-2 infection developed rhabdomyolysis and severe acute kidney injury (AKI) . A muscle biopsy confirmed findings consistent with immune-mediated necrotising myositis. Acid exposure and acid–base imbalances may profoundly affect the muscular and vascular systems. Strong acids from external sources, such as industrial chemicals, can cause corrosive tissue damage, while internal disturbances associated with metabolic disorders may disrupt cellular function and contribute to systemic complications. This article explores the potential effects of external acid exposure and internal acid–base disturbances on muscular and vascular health, including those associated with metabolic or genetic conditions. Because susceptibility to ME/CFS and complications following COVID-19 varies among individuals, further research may help determine whether genetic variant...
Read more

Impact of Penicillium on Muscle and Lung Function: What Healthcare Professionals Should Know

By
Image
Introduction While symbiotic relationships between viruses and bacteria have been documented, the possibility of a symbiosis between COVID-19 (SARS-CoV-2) and common fungal genera such as Penicillium , Aspergillus , and Trichoderma remains unexplored. This gap in research presents a potential area of interest for understanding novel microbial interactions and their implications for human health. Symbiosis Between Viruses and Bacteria – A Fascinating Partnership in the Microbial World https://swaresearch.blogspot.com/2025/07/symbiosis-between-viruses-and-bacteria.html When viruses, bacteria, or fungi—such as Penicillium —enter a host, they can trigger a range of immune responses and physiological disruptions.  Penicillium molds do not directly produce autoantibodies. However, exposure to Penicillium mold and its mycotoxins can trigger an immune response that may lead to the production of IgG antibodies , including those that could be reactive against the body's own tissues ,...
Read more

Cytokine Storm, Mast Cell Activation Syndrome (MCAS), Endothelial Dysfunction and microclots/thrombosis?

By
Update: New Research Builds on Previous Findings Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=040925&adv= Conclusions: This recent cohort study builds upon earlier work by identifying COVID-related cytokine storm (COVID-CS) through common inflammation markers and comparing it with two other cytokine storm (CS) conditions: malignancy-associated hemophagocytic lymphohistiocytosis (MN-HLH) and CAR-T–associated cytokine release syndrome (CAR-T CRS) . Among the three groups, patients treated with CAR-T therapy showed the highest survival rates , in contrast to those with COVID-CS and MN-HLH. Interestingly, the study found that CAR-T CRS and COVID-CS share similar cytokine activation pathways , suggesting a comparable immune response mechanism. In c...
Read more